Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Long-term safety, efficacy data reported from standalone MIGS procedure ➤ Positive clinical data in ongoing trial for investigational thyroid eye disease treatment ➤ Bioengineered cornea restores vision in 20 people ➤ ASCRS news and events
➤ FDA approves first standalone MIGS device ➤ Phase 3 clinical study results for inflammation, pain management nanosuspension ➤ Phase 2a clinical trial begins for investigational MGD treatment ➤ Registry created to collect data on canaloplasty ➤ ASCRS news and events
➤ FDA approves new multifocal IOL ➤ FDA approves new biosimilar ➤ First patient dosed in Phase 3 trial for investigational dry eye drug ➤ First patient dosed in Phase 2 trial investigating sustained delivery for wet AMD ➤ First patient dosed in Phase 2 study of small molecule to treat diabetic retinopathy ➤ Enrollment complete in Phase 3 trials evaluating myopia progression therapy ➤ Study emphasizes need for earlier glaucoma screening in black patients ➤ Company acquires diagnostic technology ➤ ASCRS news and events
➤ Small-aperture IOL receives FDA approval ➤ First patient enrolled in new LASIK trial ➤ Safety of sustained-release intravitreal implant confirmed ➤ Dosing complete in Phase 1/2a trial for injectable wet AMD therapy ➤ First patient dosed in light-activated optogenetic monotherapy study ➤ Phase 2 study for investigational new immunomodulator to treat dry eye disease ➤ Partnership created to develop tissue implant therapies ➤ ASCRS news and events
➤ Machine assesses cardiovascular risk with retinal scan ➤ FDA requests more info for BLA for bevacizumab ➤ Genetic variables affect NMOSD treatment ➤ Study: 12-month results from canaloplasty-trabeculotomy procedure ➤ Topline results from Phase 3 pivotal trial evaluating pupil-modulating drug ➤ ASCRS news and events
➤ Topline results from Phase 3 pivotal trial evaluating mydriasis drug ➤ First person dosed in Phase 3 trial for first-in-class dry eye candidate ➤ Phase 2 study of a novel glaucoma drop targeting non-traditional outflow ➤ Digital vision screening platform with machine learning ➤ Alcon to acquire dry eye drop and inflammation/pain drop ➤ New issue online ➤ ASCRS news and events
➤ Phase 4 results evaluating intravitreal implant ➤ Interim results for X-linked retinitis pigmentosa treatment ➤ New non-contact glaucoma laser treatment receives CE mark ➤ Companies collaborate for regenerative dry eye therapy ➤ Complimentary MIGS video series ➤ ASCRS news and events
Glaucoma Section Editor Nathan Radcliffe, MD, writes about the “chaotic events” that often thwart glaucoma patient care, how he thinks can help his patients become “antifragile,” how they can “grow from unpredictability and chaos.”
New innovations are entering the glaucoma space on a regular basis, but how do physicians discern whether (and when) to adopt them and what is that process like? Two physicians shared their considerations and experiences with bringing new techniques and technologies into practice.
Tube shunts still have important applications for glaucoma patients today and are often used for more severe disease. When categorizing tubes shunts, there are valved or non-valved options. Three physicians discussed the available non-valved tube implants, particularly how a newer option compares to older.